.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,141,587

« Back to Dashboard

Details for Patent: 7,141,587

Title:Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Inventor(s): Kania; Robert Steven (San Diego, CA), Bender; Steven Lee (Oceanside, CA), Borchardt; Allen J. (San Diego, CA), Cripps; Stephan James (San Diego, CA), Hua; Ye (Oceanside, CA), Johnson; Michael David (San Diego, CA), Johnson, Jr.; Theodore Otto (San Diego, CA), Luu; Hiep The (San Diego, CA), Palmer; Cynthia Louise (La Mesa, CA), Reich; Siegfried Heinz (Solana Beach, CA), Tempczyk-Russell; Anna Maria (Ramona, CA), Teng; Min (San Diego, CA), Thomas; Christine (West Borough, ME), Varney; Michael David (Solana Beach, CA), Wallace; Michael Brennan (San Diego, CA), Collins; Michael Raymond (San Diego, CA)
Assignee: Agouron Pharmaceuticals, Inc. (La Jolla, CA)
Filing Date:Nov 18, 2004
Application Number:10/992,146
Claims:1. A method for treating ophthalmic diseases in a mammal, comprising administering a compound of the Formula I ##STR01262## or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is a substituted or unsubstituted aryl or heteroaryl, or a group of the formula CH.dbd.CH--R.sup.3 or CH.dbd.N--R.sup.3, where R.sup.3 is a substituted or unsubstituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and R.sup.2 is a substituted or unsubstituted aryl or Y--Ar, where Y is O, S, C.dbd.CH.sub.2, C.dbd.O, S.dbd.O, SO.sub.2, CH.sub.2, CHCH.sub.3, NH, or N--(C.sub.1 C.sub.8 alkyl), and Ar is a substituted or unsubstituted aryl; to the posterior chamber of the mammal's eye proximate the macula.

2. The method of claim 1, wherein the compound of Formula I has Formula II: ##STR01263## or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof, wherein: R.sup.1 is a substituted or unsubstituted aryl or heteroaryl, or a group of the formula CH.dbd.CH--R.sup.3 or CH.dbd.N--R.sup.3, where R.sup.3 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R.sup.4 and R.sup.7 are each independently hydrogen, OH, halo, C.sub.1 C.sub.8 alkyl, C.sub.1 C.sub.8 alkoxy, C.sub.1 C.sub.8 alkenyl, aryloxy, thioaryl, CH.sub.2--OH, CH.sub.2--O--(C.sub.1 C.sub.8 alkyl), CH.sub.2--O-aryl, CH.sub.2--S--(C.sub.1 C.sub.8 alkyl), or CH.sub.2--S-aryl; R.sup.5 and R.sup.6 are each independently hydrogen, OH, halo, Z-alkyl, Z-aryl, or Z-CH.sub.2CH.dbd.CH.sub.2, where Z is O, S, NH, or CH.sub.2, and the alkyl and aryl moiety of Z-alkyl and Z-aryl are each optionally substituted.

3. The method of claim 2, wherein: R.sup.1 is a substituted or unsubstituted bicyclic heteroaryl or a group of the formula CH.dbd.CH--R.sup.3, where R.sup.3 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R.sup.4 and R.sup.7 are each independently hydrogen, OH, halo, C.sub.1 C.sub.8 alkyl, or CH.sub.2--O--(C.sub.1 C.sub.8 alkyl); and R.sup.5 and R.sup.6 are each independently hydrogen, OH, halo, Z-alkyl, Z-aryl, or Z-CH.sub.2CH.dbd.CH.sub.2, where Z is O, S, NH, or CH.sub.2, and each alkyl or aryl moiety is optionally substituted.

4. The method of claim 1, wherein the compound of Formula I has Formula III: ##STR01264## or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof, wherein: R.sup.1 is a substituted or unsubstituted aryl or heteroaryl, or a group of the formula CH.dbd.CH--R.sup.3 or CH.dbd.N--R.sup.3, where R.sup.3 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; Y is O, S, C.dbd.CH.sub.2, C.dbd.O, S.dbd.O, SO.sub.2, CH.sub.2, CHCH.sub.3, NH, or N--(C.sub.1 C.sub.8 alkyl); and R.sup.8 is a substituted or unsubstituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxyl, or aryloxyl.

5. The method of claim 1, wherein the ophthalmic disease is age related macular degeneration, diabetic retinopathy, or neovascular glaucoma.

6. The method of claim 1, wherein the compound of Formula I is administered to the ocular surface of the eye for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, including, the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/cilary, lens, choroidiretina and scelera.

7. A method for treating ophthalmic diseases in a mammal, comprising administering a compound of Formula: ##STR01265## or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or a pharmaceutically acceptable salt thereof, to the posterior chamber of the mammal's eye proximate the macula.

8. The method of claim 7, wherein the ophthalmic disease is age related macular degeneration, diabetic retinopathy, or neovascular glaucoma.

9. The method of claim 7, wherein the compound of Formula: ##STR01266## or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or a pharmaceutically acceptable salt thereof, is administered to the ocular surface of the eye for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, including, the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/cilary, lens, choroidiretina and scelera.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc